Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar® in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®...

Full description

Bibliographic Details
Main Authors: Ozra TABATABAEI-MALAZY, Masumeh NORANI, Ramin HESHMAT, Mostafa QORBANI, Afsaneh VOSOOGH, Behnaz AFRASHTEH, Farzin KAHKESHAN, Arman AJAMI, Bagher LARIJANI
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2018-08-01
Series:Iranian Journal of Public Health
Subjects:
Teriparatide
CinnoPar®
Postmenopausal osteoporosis
Clinical trial
Online Access:https://ijph.tums.ac.ir/index.php/ijph/article/view/14589

Internet

https://ijph.tums.ac.ir/index.php/ijph/article/view/14589

Similar Items